28 results on '"Peterson, Luke"'
Search Results
2. The vicinity of Earth-Moon L1 and L2 in the Hill restricted 4-body problem
3. The Vicinity of Earth-Moon L1 And L2 in the Hill Restricted 4-Body Problem
4. 34310 Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
5. Efficacité du bimékizumab dans le psoriasis en plaques modéré à sévère dans différents sous-groupes de patients : résultats groupés de trois études de phase 3, multicentriques randomisées en double aveugle
6. 27464 Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial
7. 25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
8. 27368 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial
9. 27468 Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
10. 27373 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial
11. 25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
12. 14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)
13. AML-399: A Pan-BET Degrader Shows Broad Pre-Clinical Activity in a Large Acute Myeloid Leukemia Cohort
14. AML-397: Preclinical Efficacy of a PROTAC-based MDM2 Degrader in AML models
15. Integrative Sequencing of Myeloproliferative Neoplasms
16. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
17. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
18. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
19. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth
20. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
21. Targeting p53 in CML Chronic Phase Leukemia Stem Cells
22. Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity
23. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
24. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis
25. Resistance of Listeria monocytogenes F2365 Cells to Synthetic Gastric Fluid Is Greater following Growth on Ready-to-Eat Deli Turkey Meat Than in Brain Heart Infusion Broth
26. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells
27. Intragastric Inoculation with a Cocktail of Listeria monocytogenes Strains Does Not Potentiate the Severity of Infection in A/J Mice Compared to Inoculation with the Individual Strains Comprising the Cocktail
28. Exclusion of the Nuclear Factor-κB3 (REL A) Gene as Candidate for the Multiple Endocrine Neoplasia Type 1 (MEN 1) Gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.